AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33049708 — intervention group
Group type: COMPARATOR
Intervention: Clinician‐applied Maitland talocrural joint mobilization
Number of subjects: 18
Study 36469994 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceasing opioid use
Number of subjects: 2473
Study 34397057 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented rye bran (FRB)
Number of subjects: 84
Study 33581014 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT (High-Intensity Interval Training)
Number of subjects: 24
Study 33581014 — intervention group
Group type: EXPERIMENTAL
Intervention: MIIT (Moderate-Intensity Interval Training)
Number of subjects: 24
Study 33581014 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 24
Study 35546354 — intervention group
Group type: EXPERIMENTAL
Intervention: Bench step (BS) exercise for 10 minutes after acute mental stress (MS)
Number of subjects: 15
Study 35546354 — intervention group
Group type: COMPARATOR
Intervention: Rest (RE) for 10 minutes after acute mental stress (MS)
Number of subjects: 15
Study 33477098 — intervention group
Group type: EXPERIMENTAL
Intervention: Sissoo + pineapple system
Number of subjects: 4
Study 33477098 — intervention group
Group type: EXPERIMENTAL
Intervention: Teak + pineapple system
Number of subjects: 4
Study 33477098 — intervention group
Group type: EXPERIMENTAL
Intervention: Diverse AFSs
Number of subjects: 4
Study 33477098 — intervention group
Group type: EXPERIMENTAL
Intervention: Various AFSs
Number of subjects: 4
Study 33477098 — intervention group
Group type: EXPERIMENTAL
Intervention: AFSs with pineapple
Number of subjects: 4
Study 32212519 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostemsavir (600 mg twice daily)
Number of subjects: 371
Study 32212519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 371
Study 32212519 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostemsavir plus optimized background therapy
Number of subjects: 371
Study 32212519 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label fostemsavir plus optimized background therapy
Number of subjects: 371
Study 32212519 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostemsavir
Number of subjects: 371
Study 35864019 — intervention group
Group type: EXPERIMENTAL
Intervention: Tixel treatment (thermomechanical skin device) applied across the upper and lower eyelids, three treatments with 2-week intervals.
Number of subjects: 40
Study 32956698 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal nutrition supplementation initiated preconception (Arm 1)
Number of subjects: 2421
Study 32956698 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal nutrition supplementation initiated at ∼11 weeks of gestation (Arm 2)
Number of subjects: 2421
Study 32956698 — intervention group
Group type: COMPARATOR
Intervention: No supplement (Arm 3)
Number of subjects: 2421
Study 32623637 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 20
Study 32623637 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride)
Number of subjects: 20
Study 35934006 — intervention group
Group type: EXPERIMENTAL
Intervention: Boost group
Number of subjects: 1608
Study 35934006 — intervention group
Group type: COMPARATOR
Intervention: No boost group
Number of subjects: 1608
Study 33443541 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential Chemoradiation (SCRT) - cisplatin 60-75 mg/m2 plus paclitaxel 135-175 mg/m2 in a 21-day cycle, given 2 cycles before and 2 cycles after radiotherapy.
Number of subjects: 1048
Study 33443541 — intervention group
Group type: COMPARATOR
Intervention: Concurrent Chemoradiation (CCRT) - weekly cisplatin 30-40 mg/m2.
Number of subjects: 1048
Study 33443541 — intervention group
Group type: COMPARATOR
Intervention: Radiation Alone (RT) - total dose 45-50 Gy.
Number of subjects: 1048
Study 34676663 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrexafungerp (300 mg twice for 1 day)
Number of subjects: 272
Study 34371163 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 0
Study 34371163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32698470 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving based intervention (PSI)
Number of subjects: 100
Study 32698470 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 100
Study 34625800 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright white light (BWL) for 8 weeks
Number of subjects: 51
Study 33332819 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training with an electronic resistive loading device
Number of subjects: 101
Study 33332819 — intervention group
Group type: COMPARATOR
Intervention: Traditional T‐piece protocol (control group)
Number of subjects: 101
Study 35740145 — intervention group
Group type: EXPERIMENTAL
Intervention: SI + PDT
Number of subjects: 105
Study 35740145 — intervention group
Group type: EXPERIMENTAL
Intervention: SI + LDD
Number of subjects: 105
Study 35740145 — intervention group
Group type: COMPARATOR
Intervention: SI (control)
Number of subjects: 105
Study 32803438 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser treatment with fluoride varnish
Number of subjects: 60
Study 32803438 — intervention group
Group type: COMPARATOR
Intervention: Fluoride varnish alone (control)
Number of subjects: 60
Study 33009190 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP group (5 cmH2O of CPAP during induction and emergence of anaesthesia)
Number of subjects: 42
Study 33009190 — intervention group
Group type: COMPARATOR
Intervention: Control group (induction and emergence of anaesthesia without CPAP)
Number of subjects: 42
Study 32660159 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyadic Pain Management Program (DPMP)
Number of subjects: 64
Study 32660159 — intervention group
Group type: COMPARATOR
Intervention: Control group (simple pain-related information)
Number of subjects: 64
Study 34338132 — intervention group
Group type: EXPERIMENTAL
Intervention: GP MDI 36 µg
Number of subjects: 1066
Study 34338132 — intervention group
Group type: EXPERIMENTAL
Intervention: GP MDI 18 µg
Number of subjects: 1066
Study 34338132 — intervention group
Group type: EXPERIMENTAL
Intervention: GP MDI 9 µg
Number of subjects: 1066
Study 34338132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1066
Study 34338132 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label tiotropium 2.5 µg
Number of subjects: 1066
Study 33094562 — intervention group
Group type: EXPERIMENTAL
Intervention: TXA (tranexamic acid) 500 mg into the joint after closure, knee and hip flexed at 45° for 4 h
Number of subjects: 94
Study 33094562 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline, limb fully extended
Number of subjects: 94
Study 34041699 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training Program (RTP)
Number of subjects: 63
Study 34041699 — intervention group
Group type: EXPERIMENTAL
Intervention: RTP (participants with VFA values above the median)
Number of subjects: 63
Study 34041699 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 63
Study 33167908 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid-based formula (AAF)
Number of subjects: 78
Study 33167908 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed formula (EHF)
Number of subjects: 78
Study 33167908 — intervention group
Group type: COMPARATOR
Intervention: Human milk (HM)
Number of subjects: 78
Study 35844853 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram developed for predicting overall survival (OS) probabilities.
Number of subjects: 595
Study 33037989 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth-supported intervention with individualized goal-setting and Facebook peer support
Number of subjects: 41
Study 33037989 — intervention group
Group type: COMPARATOR
Intervention: Control group accessing trackers without goal-setting or peer support
Number of subjects: 41
Study 32156763 — intervention group
Group type: EXPERIMENTAL
Intervention: HEARTPA♀N intervention (integrated smartphone and web-based intervention)
Number of subjects: 0
Study 32156763 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34142273 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Reported Outcomes Measurement Information System (PROMIS®)
Number of subjects: 0
Study 34142273 — intervention group
Group type: EXPERIMENTAL
Intervention: Latent variable models, growth models, multilevel models
Number of subjects: 0
Study 32804282 — intervention group
Group type: EXPERIMENTAL
Intervention: Free amplitude movement (FAM) shoulder exercises
Number of subjects: 465
Study 32804282 — intervention group
Group type: COMPARATOR
Intervention: Restricted amplitude movement (RAM) shoulder exercises
Number of subjects: 465
Study 32448015 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental modifications and assistive device intervention
Number of subjects: 20
Study 32448015 — intervention group
Group type: COMPARATOR
Intervention: Home exercise programmes
Number of subjects: 20
Study 33124144 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ART (CT)
Number of subjects: 101
Study 33124144 — intervention group
Group type: COMPARATOR
Intervention: CD4-driven planned treatment interruptions (PTI)
Number of subjects: 101
Study 33124144 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4/CD8 ratios
Number of subjects: 101
Study 33124144 — intervention group
Group type: EXPERIMENTAL
Intervention: CD8 cells
Number of subjects: 101
Study 33124144 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-study findings
Number of subjects: 101
Study 33124144 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term clinical outcomes
Number of subjects: 101
Study 36348453 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified TBM regimen (oral high-dose rifampicin 35 mg/kg daily and linezolid 1200 mg daily then 600 mg daily for the first 8 weeks)
Number of subjects: 0
Study 36348453 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive aspirin (200 mg daily)
Number of subjects: 0
Study 36348453 — intervention group
Group type: COMPARATOR
Intervention: WHO standard TB treatment
Number of subjects: 0
Study 36348453 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33872986 — intervention group
Group type: EXPERIMENTAL
Intervention: pelacarsen
Number of subjects: 455
Study 34420048 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous cuff pressure control (CPC) using an automated electronic device
Number of subjects: 597
Study 34420048 — intervention group
Group type: COMPARATOR
Intervention: Intermittent cuff pressure control (CPC) using a manually hand-held manometer
Number of subjects: 597
Study 34420048 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous CPC
Number of subjects: 597
Study 34420048 — intervention group
Group type: COMPARATOR
Intervention: Intermittent CPC
Number of subjects: 597
Study 33760026 — intervention group
Group type: EXPERIMENTAL
Intervention: 37% phosphoric acid gel etchant for 15 seconds
Number of subjects: 27
Study 33760026 — intervention group
Group type: EXPERIMENTAL
Intervention: Etching process
Number of subjects: 27
Study 32726530 — intervention group
Group type: EXPERIMENTAL
Intervention: Myomectomy
Number of subjects: 254
Study 32726530 — intervention group
Group type: COMPARATOR
Intervention: Uterine-artery embolization
Number of subjects: 254
Study 35585614 — intervention group
Group type: EXPERIMENTAL
Intervention: Early tracheotomy (≤ 7 days after intubation)
Number of subjects: 150
Study 35585614 — intervention group
Group type: COMPARATOR
Intervention: Late tracheotomy (≥ 10 days after intubation)
Number of subjects: 150
Study 35585614 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 150
Study 34176355 — intervention group
Group type: EXPERIMENTAL
Intervention: Achievement motivation
Number of subjects: 430
Study 34176355 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental health
Number of subjects: 430
Study 33504356 — intervention group
Group type: EXPERIMENTAL
Intervention: Online treatment decision aid
Number of subjects: 0
Study 32565534 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose S-ketamine
Number of subjects: 417
Study 32565534 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose S-ketamine
Number of subjects: 417
Study 32565534 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic ketamine
Number of subjects: 417
Study 32565534 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 417
Study 35362913 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) based case management intervention in addition to standard patient-navigation services
Number of subjects: 110
Study 35362913 — intervention group
Group type: COMPARATOR
Intervention: Standard services only
Number of subjects: 110
Study 33793754 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous tibial nerve stimulation (PTNS)
Number of subjects: 46
Study 33793754 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 46
Study 32928863 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-alanine (BA) supplementation (3.2 g per day) during 8-10 week pulmonary rehabilitation program with NLPE training.
Number of subjects: 222
Study 32928863 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-alanine (BA) supplementation (3.2 g per day) during 8-10 week pulmonary rehabilitation program with NMES.
Number of subjects: 222
Study 32928863 — intervention group
Group type: COMPARATOR
Intervention: Placebo during 8-10 week pulmonary rehabilitation program with NLPE training.
Number of subjects: 222
Study 32928863 — intervention group
Group type: COMPARATOR
Intervention: Placebo during 8-10 week pulmonary rehabilitation program with NMES.
Number of subjects: 222
Study 32928863 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-alanine (BA) supplementation (3.2 g per day)
Number of subjects: 222
Study 32928863 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study 36208061 — intervention group
Group type: EXPERIMENTAL
Intervention: SBIRT+RMC-PC
Number of subjects: 266
Study 36208061 — intervention group
Group type: COMPARATOR
Intervention: SBIRT
Number of subjects: 266
Study 34706665 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH-ant half-dose (Group 1)
Number of subjects: 314
Study 34706665 — intervention group
Group type: COMPARATOR
Intervention: GnRH-ant full-dose (Group 2)
Number of subjects: 314
Study 34706665 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI < 25 (subgroup C1)
Number of subjects: 314
Study 34706665 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI ≥ 25 (subgroup D1)
Number of subjects: 314
Study 33017045 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,064 nm Q-switched Nd-YAG laser (QSNYL)
Number of subjects: 28
Study 33017045 — intervention group
Group type: COMPARATOR
Intervention: Modified Kligman's triple combination (TC)
Number of subjects: 28
Study 34583744 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time PRO data captured with electronic mobile devices, weekly requests via an app to complete the PRO survey.
Number of subjects: 1000
Study 34583744 — intervention group
Group type: COMPARATOR
Intervention: Usual care, prompted by the app every 3 months to participate in the PRO survey, no alarm triggered.
Number of subjects: 1000
Study 33709142 — intervention group
Group type: EXPERIMENTAL
Intervention: Remdesivir (100 mg/day for 5 days)
Number of subjects: 38
Study 33709142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 36461653 — intervention group
Group type: EXPERIMENTAL
Intervention: saxagliptin
Number of subjects: 7
Study 36461653 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 7
Study 34752935 — intervention group
Group type: EXPERIMENTAL
Intervention: AT-001 (caficrestat) 1500 mg BID for up to 14 days
Number of subjects: 10
Study 34752935 — intervention group
Group type: COMPARATOR
Intervention: Matched Control Group 1 (MC1)
Number of subjects: 10
Study 34752935 — intervention group
Group type: COMPARATOR
Intervention: Matched Control Group 2 (MC2)
Number of subjects: 10
Study 36346668 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Minds Program (HMP) meditation app
Number of subjects: 662
Study 36346668 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control condition
Number of subjects: 662
Study 32027150 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflective parenting program
Number of subjects: 103
Study 32027150 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 103
Study 35428973 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 3871
Study 35428973 — intervention group
Group type: COMPARATOR
Intervention: Multivessel percutaneous coronary intervention (PCI)
Number of subjects: 3871
Study 34390648 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative continuous positive airway pressure
Number of subjects: 0
Study 34390648 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 35781822 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-hour asynchronous video training
Number of subjects: 84
Study 35781822 — intervention group
Group type: EXPERIMENTAL
Intervention: Spaced-education condition
Number of subjects: 84
Study 35781822 — intervention group
Group type: COMPARATOR
Intervention: Baseline to post-video
Number of subjects: 84
Study 33479931 — intervention group
Group type: EXPERIMENTAL
Intervention: Home hospital care (nurse and physician home visits, intravenous medications, remote monitoring, video communication, point‐of‐care testing)
Number of subjects: 36
Study 33479931 — intervention group
Group type: EXPERIMENTAL
Intervention: Home hospital care
Number of subjects: 36
Study 33479931 — intervention group
Group type: COMPARATOR
Intervention: Traditional hospital care (control)
Number of subjects: 36
Study 36329548 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU plus hearing aids (n = 42)
Number of subjects: 83
Study 36329548 — intervention group
Group type: COMPARATOR
Intervention: Education and advice (treatment as usual, TAU) (n = 41)
Number of subjects: 83
Study 33772130 — intervention group
Group type: EXPERIMENTAL
Intervention: Ideal facial images on Instagram
Number of subjects: 132
Study 33772130 — intervention group
Group type: COMPARATOR
Intervention: Neutral images of nature
Number of subjects: 132
Study 33545441 — intervention group
Group type: EXPERIMENTAL
Intervention: Early manual rotation
Number of subjects: 65
Study 33545441 — intervention group
Group type: COMPARATOR
Intervention: Control (expectant management)
Number of subjects: 65
Study 36178723 — intervention group
Group type: EXPERIMENTAL
Intervention: IMB model-based online education program
Number of subjects: 3867
Study 36178723 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 3867
Study 32964933 — intervention group
Group type: EXPERIMENTAL
Intervention: Rural children
Number of subjects: 572
Study 32964933 — intervention group
Group type: COMPARATOR
Intervention: Urban children
Number of subjects: 572
Study 32964933 — intervention group
Group type: EXPERIMENTAL
Intervention: Rural vs Urban
Number of subjects: 572
Study 36129719 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral standard rTMS
Number of subjects: 172
Study 36129719 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral theta burst stimulation (TBS)
Number of subjects: 172
Study 32520656 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic scapular recognition exercise
Number of subjects: 0
Study 32520656 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 35103799 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 2 mg/mL
Number of subjects: 10
Study 35103799 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinzolamide 10 mg/mL
Number of subjects: 10
Study 35103799 — intervention group
Group type: COMPARATOR
Intervention: Control (fellow eyes)
Number of subjects: 10
Study 35103799 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine and Brinzolamide
Number of subjects: 10
Study 34127741 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledgeable communities about onagers
Number of subjects: 0
Study 34127741 — intervention group
Group type: COMPARATOR
Intervention: Traditional methods
Number of subjects: 0
Study 34127741 — intervention group
Group type: EXPERIMENTAL
Intervention: Habitat connectivity models
Number of subjects: 0
Study 34127741 — intervention group
Group type: EXPERIMENTAL
Intervention: Roads cutting off core areas
Number of subjects: 0
Study 35900549 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel/carboplatin (taxane-based)
Number of subjects: 0
Study 35900549 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin/5FU (non-taxane-based)
Number of subjects: 0
Study 33221237 — intervention group
Group type: EXPERIMENTAL
Intervention: CAC of >400
Number of subjects: 3075
Study 33221237 — intervention group
Group type: EXPERIMENTAL
Intervention: CAC of >100
Number of subjects: 3075
Study 35808843 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelial protocol (Nicorandil, L-arginine, folate, Nebivolol, atorvastatin)
Number of subjects: 42
Study 35808843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 35808843 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelial protocol
Number of subjects: 42
Study 33357007 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (16 mg/day) during resistance training
Number of subjects: 26
Study 33357007 — intervention group
Group type: COMPARATOR
Intervention: Placebo during resistance training
Number of subjects: 26
Study 616538626 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive servo-ventilation
Number of subjects: 51
Study 616538626 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 51
Study 34608719 — intervention group
Group type: EXPERIMENTAL
Intervention: The Growth Factory (TGF)
Number of subjects: 119
Study 34608719 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 119
Study 34271902 — intervention group
Group type: EXPERIMENTAL
Intervention: Florence (SMS communication system)
Number of subjects: 65
Study 34271902 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 65
Study 33443925 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tranexamic acid (TXA) 1300 mg per dose, three doses: 2 hours before surgery, and 6 and 12 hours after surgery.
Number of subjects: 102